The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Recent clinical trends in Toll‐like receptor targeting therapeutics
Open accessAbstract
Toll‐like receptors (TLRs) are germline‐encoded receptors that are central to innate and adaptive immune responses. Owing to their vital role in inflammation, TLRs are rational targets in clinics; thus, many ligands and biologics have been reported to overcome the progression of various inflammatory and malignant conditions and support the immune system. For each TLR, at least one, and often many, drug formulations are being evaluated. Ligands reported as stand‐alone drugs may also be reported based on their use in combinatorial therapeutics as adjuvants. Despite their profound efficacy in TLR‐modulation in preclinical studies, multiple drugs have been terminated at different stages of clinical trials. Here, TLR modulating drugs that have been evaluated in clinical trials are discussed, along with their mode of action, suggestive failure reasons, and ways to improve the clinical outcomes. This review presents recent advances in TLR‐targeting drugs and provides directions for more successful immune system manipulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301
The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex
Park, B. S., Song, D. H., Kim, H. M., Choi, B.-S., Lee, H., & Lee, J.-O. (2009) · Nature · doi:10.1038/nature07830 · Cited by 2,428
Signaling to NF-κB by Toll-like receptors
Kawai, T., & Akira, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.002 · Cited by 2,388
TAK1 is a ubiquitin-dependent kinase of MKK and IKK
Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J.-I., & Chen, Z. J. (2001) · Nature · doi:10.1038/35085597 · Cited by 2,125
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C., & Chen, Z. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00126-4 · Cited by 1,872
Recognition of single-stranded RNA viruses by Toll-like receptor 7
Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400937101 · Cited by 1,861
NF-κB, the first quarter-century: remarkable progress and outstanding questions
Hayden, M. S., & Ghosh, S. (2012) · Genes & Development · doi:10.1101/gad.183434.111 · Cited by 1,693
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide
Jin, M. S., Kim, S. E., Heo, J. Y., Lee, M. E., Kim, H. M., Paik, S.-G., Lee, H., & Lee, J.-O. (2007) · Cell · doi:10.1016/j.cell.2007.09.008 · Cited by 1,344
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
Lomaga, M. A., Yeh, W.-C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S., et al. (1999) · Genes & Development · doi:10.1101/gad.13.8.1015 · Cited by 1,267
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β
Kagan, J. C., Su, T., Horng, T., Chow, A., Akira, S., & Medzhitov, R. (2008) · Nature Immunology · doi:10.1038/ni1569 · Cited by 1,253
Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran
Kim, H. M., Park, B. S., Kim, J.-I., Kim, S. E., Lee, J., Oh, S. C., Enkhbayar, P., Matsushima, N., Lee, H., Yoo, O. J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.002 · Cited by 1,177
Self-citationHelical Assembly in the MyD88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling
Lin, S.-C., Lo, Y.-C., & Wu, H. (2010) · Nature · doi:10.1038/nature09121 · Cited by 1,111 · cited 1×
“This inter‐domain interaction results in a large multimeric molecule, referred to as myddosome, the phosphorylation of which leads to the activation and dimerization of tumor necrosis factor (TNF) receptor–associated factor 6 (TRAF6).(30) TRAF6, an E3 ligase that is activated via autoubiquitination in an sequestosome…”
BackgroundChristensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., & Shlomchik, M. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.013 · Cited by 1,090
A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria
Zhang, D., Zhang, G., Hayden, M. S., Greenblatt, M. B., Bussey, C., Flavell, R. A., & Ghosh, S. (2004) · Science · doi:10.1126/science.1094351 · Cited by 1,004
Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., Chang, B., Duramad, O., & Coffman, R. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050914 · Cited by 928
Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.2194 · Cited by 812
Recognition of Lipopeptide Patterns by Toll-like Receptor 2-Toll-like Receptor 6 Heterodimer
Kang, J. Y., Nan, X., Jin, M. S., Youn, S.-J., Ryu, Y. H., Mah, S., Han, S. H., Lee, H., Paik, S.-G., & Lee, J.-O. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.018 · Cited by 765
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo
Shim, J.-H., Xiao, C., Paschal, A. E., Bailey, S. T., Rao, P., Hayden, M. S., Lee, K.-Y., Bussey, C., Steckel, M., Tanaka, N., et al. (2005) · Genes & Development · doi:10.1101/gad.1360605 · Cited by 738
Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
The Structural Biology of Toll-like Receptors
Botos, I., Segal, D. M., & Davies, D. R. (2011) · Structure · doi:10.1016/j.str.2011.02.004 · Cited by 693
MyD88: a central player in innate immune signaling
Deguine, J., & Barton, G. M. (2014) · F1000Prime Reports · doi:10.12703/p6-97 · Cited by 692
TLR3: Interferon induction by double-stranded RNA including poly(I:C)☆
MATSUMOTO, M., & SEYA, T. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.005 · Cited by 685
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes
Martin, G. S. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.50 · Cited by 680
Toll-like receptors in immunity and inflammatory diseases: Past, present, and future
Vijay, K. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.002 · Cited by 643
Complexity of Danger: The Diverse Nature of Damage-associated Molecular Patterns
Schaefer, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.619304 · Cited by 622
Has the mortality of septic shock changed with time?
Friedman, G., Silva, E., & Vincent, J.-L. (1998) · Critical Care Medicine · doi:10.1097/00003246-199812000-00045 · Cited by 607
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines
Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000702 · Cited by 606
Crystal Structure of Human Toll-Like Receptor 3 (TLR3) Ectodomain
Choe, J., Kelker, M. S., & Wilson, I. A. (2005) · Science · doi:10.1126/science.1115253 · Cited by 602
Janssens, S., & Beyaert, R. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00053-4 · Cited by 559
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Inpatient care for septicemia or sepsis: a challenge for patients and hospitals.
Hall, M. J., Williams, S. N., DeFrances, C. J., & Golosinskiy, A. (2011) · PubMed · Cited by 472
Crystal Structures of Human MD-2 and Its Complex with Antiendotoxic Lipid IVa
Ohto, U., Fukase, K., Miyake, K., & Satow, Y. (2007) · Science · doi:10.1126/science.1139111 · Cited by 471
Innate immunity to Toxoplasma gondii infection
Yarovinsky, F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3598 · Cited by 462
Zhang, Z., Ohto, U., Shibata, T., Krayukhina, E., Taoka, M., Yamauchi, Y., Tanji, H., Isobe, T., Uchiyama, S., Miyake, K., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.011 · Cited by 461
Han, C., Jin, J., Xu, S., Liu, H., Li, N., & Cao, X. (2010) · Nature Immunology · doi:10.1038/ni.1908 · Cited by 455
A Deubiquitinase That Regulates Type I Interferon Production
Kayagaki, N., Phung, Q., Chan, S., Chaudhari, R., Quan, C., O'Rourke, K. M., Eby, M., Pietras, E., Cheng, G., Bazan, J. F., et al. (2007) · Science · doi:10.1126/science.1145918 · Cited by 452
TLR-dependent T cell activation in autoimmunity
Mills, K. H. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3095 · Cited by 443
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Hwang, T. J., Carpenter, D., Lauffenburger, J. C., Wang, B., Franklin, J. M., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6008 · Cited by 442
Why clinical trial outcomes fail to translate into benefits for patients
Heneghan, C., Goldacre, B., & Mahtani, K. R. (2017) · Trials · doi:10.1186/s13063-017-1870-2 · Cited by 404
Toll-like receptor 8 senses degradation products of single-stranded RNA
Tanji, H., Ohto, U., Shibata, T., Taoka, M., Yamauchi, Y., Isobe, T., Miyake, K., & Shimizu, T. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2943 · Cited by 404
Zähringer, U., Lindner, B., Inamura, S., Heine, H., & Alexander, C. (2008) · Immunobiology · doi:10.1016/j.imbio.2008.02.005 · Cited by 403
Synergy and Cross-Tolerance Between Toll-Like Receptor (TLR) 2- and TLR4-Mediated Signaling Pathways
Sato, S., Nomura, F., Kawai, T., Takeuchi, O., Mühlradt, P. F., Takeda, K., & Akira, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7096 · Cited by 401
Flagellin as an Adjuvant: Cellular Mechanisms and Potential
Mizel, S. B., & Bates, J. T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002156 · Cited by 399 · cited 1×
“Additionally, small molecules to block the TLR5‐flagellin interaction are being tested in preclinical studies.(120) In the majority of therapeutic settings, ligands for TLR5 act as adjuvants rather than as stand‐alone drugs, enhancing the efficacy and potency of vaccine candidates (Table 5).”
BackgroundIdentification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells
Chuang, T.-H., & Ulevitch, R. J. (2001) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00289-x · Cited by 397
Airway Mucin Concentration as a Marker of Chronic Bronchitis
Kesimer, M., Ford, A. A., Ceppe, A., Radicioni, G., Cao, R., Davis, C. W., Doerschuk, C. M., Alexis, N. E., Anderson, W. H., Henderson, A. G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701632 · Cited by 380
Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9
Ohto, U., Shibata, T., Tanji, H., Ishida, H., Krayukhina, E., Uchiyama, S., Miyake, K., & Shimizu, T. (2015) · Nature · doi:10.1038/nature14138 · Cited by 377 · cited 1×
“CpG‐DNA binding with TLR9 is symmetric and they form a stoichiometric complex of 2:2, as DNA is recognized by both TLR9 monomers, particularly via the amino‐terminal fragment (LRRNT–LRR10) from one protomer and the carboxy‐terminal fragment (LRR20–LRR22) from the other.(142) CpG‐DNA‐based TLR9 inhibition is mediated b…”
BackgroundCasanova, J.-L., Abel, L., & Quintana-Murci, L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101335 · Cited by 366
Gao, W., Xiong, Y., Li, Q., & Yang, H. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00508 · Cited by 353
Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands
Tanji, H., Ohto, U., Shibata, T., Miyake, K., & Shimizu, T. (2013) · Science · doi:10.1126/science.1229159 · Cited by 348
Nickerson, K. M., Christensen, S. R., Shupe, J., Kashgarian, M., Kim, D., Elkon, K., & Shlomchik, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902592 · Cited by 347
Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria
Feuillet, V., Medjane, S., Mondor, I., Demaria, O., Pagni, P. P., Galán, J. E., Flavell, R. A., & Alexopoulou, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605200103 · Cited by 336
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Jo, E.-K., Yang, C.-S., Choi, C. H., & Harding, C. V. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.00914.x · Cited by 331
Van Der Heijden, I. M., Wilbrink, B., Tchetverikov, I., Schrijver, I. A., Schouls, L. M., Hazenberg, M. P., Breedveld, F. C., & Tak, P. P. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200003)43:3<593::aid-anr16>3.0.co;2-1 · Cited by 306
Saitoh, T., Tun-Kyi, A., Ryo, A., Yamamoto, M., Finn, G., Fujita, T., Akira, S., Yamamoto, N., Lu, K. P., & Yamaoka, S. (2006) · Nature Immunology · doi:10.1038/ni1347 · Cited by 303
Savva, A., & Roger, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00387 · Cited by 261
Human TLR10 is an anti-inflammatory pattern-recognition receptor
Oosting, M., Cheng, S.-C., Bolscher, J. M., Vestering-Stenger, R., Plantinga, T. S., Verschueren, I. C., Arts, P., Garritsen, A., van Eenennaam, H., Sturm, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410293111 · Cited by 260
Differential expression of Toll-like receptor 2 in human cells
Flo, T. H., Halaas, Ø., Torp, S., Ryan, L., Lien, E., Dybdahl, B., Sundan, A., & Espevik, T. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.3.474 · Cited by 255
TLR1- and TLR6-independent Recognition of Bacterial Lipopeptides
Buwitt-Beckmann, U., Heine, H., Wiesmüller, K.-H., Jung, G., Brock, R., Akira, S., & Ulmer, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512525200 · Cited by 255
Shi, M., Deng, W., Bi, E., Mao, K., Ji, Y., Lin, G., Wu, X., Tao, Z., Li, Z., Cai, X., et al. (2008) · Nature Immunology · doi:10.1038/ni1577 · Cited by 254
Direct, Noncatalytic Mechanism of IKK Inhibition by A20
Skaug, B., Chen, J., Du, F., He, J., Ma, A., & Chen, Z. J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.09.015 · Cited by 251
Alving, C. R., Peachman, K. K., Rao, M., & Reed, S. G. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.03.008 · Cited by 225
Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice
Santiago-Raber, M.-L., Dunand-Sauthier, I., Wu, T., Li, Q.-Z., Uematsu, S., Akira, S., Reith, W., Mohan, C., Kotzin, B. L., & Izui, S. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.11.001 · Cited by 219
Ioannidis, I., Ye, F., McNally, B., Willette, M., & Flaño, E. (2013) · Journal of Virology · doi:10.1128/jvi.01956-12 · Cited by 216
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Smits, E. L. J. M., Ponsaerts, P., Berneman, Z. N., & Van Tendeloo, V. F. I. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0097 · Cited by 215
Janssen, H. L. A., Brunetto, M. R., Kim, Y. J., Ferrari, C., Massetto, B., Nguyen, A.-H., Joshi, A., Woo, J., Lau, A. H., Gaggar, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.027 · Cited by 203
The Effects of TLR Activation on T-Cell Development and Differentiation
Jin, B., Sun, T., Yu, X.-H., Yang, Y.-X., & Yeo, A. E. T. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/836485 · Cited by 201
Fukata, M., Shang, L., Santaolalla, R., Sotolongo, J., Pastorini, C., España, C., Ungaro, R., Harpaz, N., Cooper, H. S., Elson, G., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21527 · Cited by 199
Toll-like receptors and chronic inflammation in rheumatic diseases: new developments
Joosten, L. A. B., Abdollahi-Roodsaz, S., Dinarello, C. A., O'Neill, L., & Netea, M. G. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.61 · Cited by 195
TLRs: Linking inflammation and breast cancer
Bhatelia, K., Singh, K., & Singh, R. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.035 · Cited by 188
Yuk, J.-M., Shin, D.-M., Lee, H.-M., Kim, J.-J., Kim, S.-W., Jin, H. S., Yang, C.-S., Park, K. A., Chanda, D., Kim, D.-K., et al. (2011) · Nature Immunology · doi:10.1038/ni.2064 · Cited by 188
Self-citationSpachidou, M. P., Bourazopoulou, E., Maratheftis, C. I., Kapsogeorgou, E. K., Moutsopoulos, H. M., Tzioufas, A. G., & Manoussakis, M. N. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03311.x · Cited by 186
McCarthy, C. G., Goulopoulou, S., Wenceslau, C. F., Spitler, K., Matsumoto, T., & Webb, R. C. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00328.2013 · Cited by 182
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V. C., Henderson, K. E., Howbert, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1625 · Cited by 176
TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS
Wang, Y., Su, L., Morin, M. D., Jones, B. T., Whitby, L. R., Surakattula, M. M. R. P., Huang, H., Shi, H., Choi, J. H., Wang, K.-W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525639113 · Cited by 169
Mäkelä, S. M., Strengell, M., Pietilä, T. E., Österlund, P., & Julkunen, I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0808503 · Cited by 167
Toll-like Receptor 9, CpG DNA and Innate Immunity
Ashkar, A., & Rosenthal, K. (2002) · Current Molecular Medicine · doi:10.2174/1566524023362159 · Cited by 166
Parsing clinical success rates
Mullard, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.136 · Cited by 165
Huang, L., Xu, H., & Peng, G. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2018.4 · Cited by 164
Negative regulatory approaches to the attenuation of Toll-like receptor signaling
Anwar, M. A., Basith, S., & Choi, S. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.28 · Cited by 161
Self-citationFukata, M., Hernandez, Y., Conduah, D. E., Cohen, J., Chen, A., Breglio, K. J., Goo, T., Hsu, D. S., Xu, R., & Abreu, M. T. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20880 · Cited by 161
Taylor, D. N., Treanor, J. J., Strout, C., Johnson, C., Fitzgerald, T., Kavita, U., Ozer, K., Tussey, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.001 · Cited by 160
RNA-targeted therapeutics in cancer clinical trials: Current status and future directions
Barata, P. C., Sood, A. K., & Hong, D. S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.004 · Cited by 159
Regulation of B‐cell responses by Toll‐like receptors
Browne, E. P. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03587.x · Cited by 156
Small-molecule inhibition of TLR8 through stabilization of its resting state
Zhang, S., Hu, Z., Tanji, H., Jiang, S., Das, N., Li, J., Sakaniwa, K., Jin, J., Bian, Y., Ohto, U., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2518 · Cited by 154
A conserved TLR5 binding and activation hot spot on flagellin
Song, W. S., Jeon, Y. J., Namgung, B., Hong, M., & Yoon, S. (2017) · Scientific Reports · doi:10.1038/srep40878 · Cited by 153
Pålsson‐McDermott, E. M., Doyle, S., McGettrick, A. F., Hardy, M., Husebye, H., Banahan, K., Gong, M., Golenbock, D. T., Espevik, T., & O'Neill, L. A. J. (2009) · Nature Immunology · doi:10.1038/ni.1727 · Cited by 151
Ramirez‐Ortiz, Z. G., Specht, C. A., Wang, J. P., Lee, C. K., Bartholomeu, D. C., Gazzinelli, R. T., & Levitz, S. M. (2008) · Infection and Immunity · doi:10.1128/iai.00047-08 · Cited by 151
Wang, Y., Abel, K., Lantz, K., Krieg, A. Μ., McChesney, M. B., & Miller, C. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14355-14370.2005 · Cited by 139
Small-Molecule Inhibitors of the TLR3/dsRNA Complex
Cheng, K., Wang, X., & Yin, H. H. (2011) · Journal of the American Chemical Society · doi:10.1021/ja111312h · Cited by 129
TLR Cross-talk Confers Specificity to Innate Immunity
Tan, R. S. T., Ho, B., Leung, B. P. L., & Ding, J. L. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.921164 · Cited by 129
Reilly, M., Miller, R. M., Thomson, M., Patris, V., Ryle, P. R., McLoughlin, L., Mutch, P. J., Gilboy, P., Miller, C., Broekema, M., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.150 · Cited by 124
IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis
Cataisson, C., Salcedo, R., Hakim, S., Moffitt, A. B., Wright, L. N., Yi, M., Stephens, R. M., Dai, R., Lyakh, L. A., Schenten, D., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20101355 · Cited by 116
Arslan, F., Houtgraaf, J. H., Keogh, B., Kazemi, K., de Jong, R., McCormack, W. J., O'Neill, L. A. J., McGuirk, P., Timmers, L., Smeets, M. B., et al. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.967596 · Cited by 113
Ginaldi, L., & Martinis, M. D. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160907162546 · Cited by 111
Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle
Dar, P., Kalaivanan, R., Sied, N., Edao, B. M., Kishore, S., Suryanarayana, V. V. S., & Kondabattula, G. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.078 · Cited by 109
O’Reilly, S., & Duffy, L. (2016) · ImmunoTargets and Therapy · doi:10.2147/itt.s89795 · Cited by 108
Similar Structures but Different Roles – An Updated Perspective on TLR Structures
Manavalan, B., Basith, S., & Choi, S. (2011) · Frontiers in Physiology · doi:10.3389/fphys.2011.00041 · Cited by 103
Self-citationTLR3 activation efficiency by high or low molecular mass poly I:C
Zhou, Y., Guo, M. S., Wang, X., Li, J., Wang, Y., Ye, L., Dai, M., Zhou, L., Persidsky, Y., & Ho, W. (2012) · Innate Immunity · doi:10.1177/1753425912459975 · Cited by 103
Jagannathan‐Bogdan, M., Hastürk, H., Liang, Y., Shin, H., Hetzel, J. T., Kantarcı, A., Rubin, D. J., McDonnell, M. E., Dyke, T. E. V., Ganley-Leal, L. M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901517 · Cited by 101
How flagellin and toll-like receptor 5 contribute to enteric infection
Steiner, T. S. (2007) · Infection and Immunity · doi:10.1128/iai.01506-06 · Cited by 97
Arias, M. A., Roey, G. A. V., Tregoning, J. S., Moutaftsi, M., Coler, R. N., Windish, H. P., Reed, S. G., Carter, D., & Shattock, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041144 · Cited by 97
Advances in Toll-like receptor biology: Modes of activation by diverse stimuli
Bryant, C. E., Gay, N. J., Heymans, S. R. B., Sacre, S. M., Schaefer, L., & Midwood, K. S. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1033511 · Cited by 96
Ta, N., Li, Y., Schuyler, C. A., Lopes-Virella, M. F., & Huang, Y. Q. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.08.064 · Cited by 96
Thomas, L. (1972) · New England Journal of Medicine · doi:10.1056/nejm197209142871109 · Cited by 96
Innate Immunity Mediated by TLR5 as a Novel Antiinflammatory Target for Cystic Fibrosis Lung Disease
Blohmke, C. J., Victor, R. E., Hirschfeld, A. F., Elias, I. M., Hancock, D. G., Lane, C. R., Davidson, A. G. F., Wilcox, P., Smith, K. D., Overhage, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7764 · Cited by 94
Kox, M., van Velzen, J. F., Pompe, J. C., Hoedemaekers, C., van der Hoeven, J. G., & Pickkers, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.096 · Cited by 92
The role of toll-like receptors in systemic lupus erythematosus
Rahman, A. H., & Eisenberg, R. A. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0034-3 · Cited by 90
Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation
Hu, W., Jain, A., Gao, Y., Dozmorov, I. M., Mandraju, R., Wakeland, E. K., & Pasare, C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510760112 · Cited by 87
Dendritic cell targeted vaccines: Recent progresses and challenges
Chen, P., Liu, X., Sun, Y., Zhou, P., Wang, Y., & Zhang, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1105415 · Cited by 85
Toshchakov, V. Y., Fenton, M. J., & Vogel, S. N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2655 · Cited by 81
Monnet, E., Lapeyre, G., van Poelgeest, E. P., Jacqmin, P., de Graaf, K., Reijers, J. A. A., Moerland, M., Burggraaf, J., & de Min, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.522 · Cited by 79
Toshchakov, V. Y., Szmacinski, H., Couture, L. A., Lakowicz, J. R., & Vogel, S. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002424 · Cited by 77
Dowling, D. J., Hamilton, C. M., & O’Neill, S. M. (2008) · Cytokine · doi:10.1016/j.cyto.2007.11.020 · Cited by 74
Yusuf, N., Nasti, T. H., Long, J., Naseemuddin, M., Lucas, A. P., Xu, H., & Elmets, C. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5219 · Cited by 72
Casale, T. B., Cole, J., Beck, E. C., Vogelmeier, C. F., Willers, J., Lassen, C., Hammann‐Haenni, A., Trokan, L., Saudan, P., & Wechsler, M. E. (2015) · Allergy · doi:10.1111/all.12663 · Cited by 69
Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Lin, Y.-T., Verma, A., & Hodgkinson, C. P. (2012) · Current Genomics · doi:10.2174/138920212803759712 · Cited by 68
Lima, C. X., Souza, D. G., Amaral, F. A., Fagundes, C. T., Rodrigues, I. P. S., Alves-Filho, J. C., Kosco‐Vilbois, M. H., Ferlin, W. G., Shang, L., Elson, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132336 · Cited by 64
Biotech R&D spend jumps by more than 15%
Mullard, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.135 · Cited by 62
Maeda, K., & Akira, S. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.003 · Cited by 62
Zhang, L. J., Dewan, V., & Yin, H. H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00419 · Cited by 62
Powell-Smith, A., & Goldacre, B. M. (2016) · F1000Research · doi:10.12688/f1000research.10010.1 · Cited by 60
Ruzsa, Á., Şen, M., Evans, M., Lee, L. W., Hidéghety, K., Rottey, S., Klimak, P., Holečková, P., Fayette, J., Csőszi, T., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0117-2 · Cited by 59
Autoinhibition and relief mechanism by the proteolytic processing of Toll-like receptor 8
Tanji, H., Ohto, U., Motoi, Y., Shibata, T., Miyake, K., & Shimizu, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516000113 · Cited by 57
Hossain, M. J., Morandi, E., Tănăsescu, R., Frakich, N., Caldano, M., Onion, D., Faraj, T. A., Erridge, C., & Gran, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00457 · Cited by 57
TLR4/MD2 specific peptides stalled in vivo LPS-induced immune exacerbation
Park, S.-H., Shin, H., Shah, M., Cho, H.-Y., Anwar, M. A., Achek, A., Kwon, H., Byugsung, L., Yoo, T. H., & Choi, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.023 · Cited by 56
Self-citationGarcia, P. V., Seiva, F. R. F., Carniato, A. P., Júnior, W. D. M., Durán, N., Macedo, A. M., Oliveira, A. G., Romih, R., Nunes, I. D. S., Nunes, O. D. S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2474-z · Cited by 52
Mett, V. L., Komarova, E. A., Greene, K. M., Bespalov, I. A., Brackett, C. M., Gillard, B. M., Gleiberman, A. S., Toshkov, I., Aygun‐Sunar, S., Johnson, C., et al. (2017) · Oncogene · doi:10.1038/onc.2017.346 · Cited by 47
Toshkov, I. A., Gleiberman, A. S., Mett, V. L., Hutson, A. D., Singh, A. K., Gudkov, A. V., & Burdelya, L. G. (2017) · Radiation Research · doi:10.1667/rr14514.1 · Cited by 46
Yang, H., Brackett, C. M., Morales-Tirado, V. M., Li, Z., Zhang, Q., Wilson, M. W., Benjamin, C. A., Harris, W. B., Waller, E. K., Gudkov, A. V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6500 · Cited by 45
Karlsen, M., Jonsson, R., Brun, J. G., Appel, S., & Hansen, T. F. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12368 · Cited by 42
Zhan, R., Han, Q., Zhang, C., Tian, Z., & Zhang, J. (2015) · Infection and Immunity · doi:10.1128/iai.02870-14 · Cited by 42
Biggadike, K., Ahmed, M., Ball, D. I., Coe, D. M., Dalmas, D. A., Edwards, C. D., Gibbon, B. H., Hardy, C. J., Hermitage, S. A., Hessey, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01647 · Cited by 42
The Second Messenger Phosphatidylinositol-5-Phosphate Facilitates Antiviral Innate Immune Signaling
Kawasaki, T., Takemura, N., Standley, D. M., Akira, S., & Kawai, T. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.011 · Cited by 39
Silkoff, P. E., Flavin, S. K., Gordon, R. M., Loza, M. J., Sterk, P. J., Lutter, R., Diamant, Z., Turner, R. B., Lipworth, B. J., Proud, D., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.027 · Cited by 39
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy
Monk, B. J., Facciabene, A., Brady, W. E., Aghajanian, C. A., Fracasso, P. M., Walker, J. L., Lankes, H. A., Manjarrez, K. L., Danet-Desnoyers, G.-A., Bell‐McGuinn, K. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1453 · Cited by 37
Durai, P., Govindaraj, R., & Choi, S.-D. (2013) · The FEBS Journal · doi:10.1111/febs.12541 · Cited by 36
Self-citationThe TLR2 is activated by sporozoites and suppresses intrahepatic rodent malaria parasite development
Zheng, H., Tan, Z., Zhou, T., Zhu, F., Ding, Y. P., Liu, T., Wu, Y., & Xu, W. (2015) · Scientific Reports · doi:10.1038/srep18239 · Cited by 35
Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants
Pomerenke, A., Lea, S., Herrick, S. E., Lindsay, M. A., & Singh, D. (2016) · International Journal of COPD · doi:10.2147/copd.s105156 · Cited by 34
Ellis, A. K., Tsitoura, D. C., Quint, D. J., Powley, W., & Lee, L. A. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12974 · Cited by 32
Deifl, S., Kitzmüller, C., Steinberger, P., Himly, M., Jahn‐Schmid, B., Fischer, G., Zlabinger, G. J., & Bohle, B. (2014) · Allergy · doi:10.1111/all.12501 · Cited by 29
Vo, M.-C., Lee, H.-J., Kim, J.-S., Hoang, M.-D., Choi, N.-R., Rhee, J. H., Lakshmanan, V., Shin, S.-J., & Lee, J. (2015) · Oncotarget · doi:10.18632/oncotarget.5281 · Cited by 27
Self-citationNovel antagonist antibody to TLR3 blocks poly(I:C)-induced inflammation in vivo and in vitro
Bunting, R. A., Duffy, K. E., Lamb, R. J., Mateo, L. R. S., Smalley, K. A., Raymond, H. A., Liu, X., Petley, T., Fisher, J., Beck, H., et al. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.10.008 · Cited by 23
Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis
Qin, M., Li, Y., Xu, Y., & Wu, H. (2014) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2013.861481 · Cited by 20
JULIAN, M. W., Strange, H. R., Ballinger, M. N., Hotchkiss, R. S., Papenfuss, T. L., & Crouser, E. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132921 · Cited by 15
Jelaska (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200010)43:10 · Cited by 2
Shah, M., & Choi, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101496 · Cited by 2
Self-citationAtif, S. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_639 · Cited by 1
Cited by
Combating Implant Infections: Shifting Focus from Bacteria to Host
Amin Yavari, S., Castenmiller, S. M., van Strijp, J. A. G., & Croes, M. (2020) · Advanced Materials · doi:10.1002/adma.202002962 · Cited by 257
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions
Squillace, S., & Salvemini, D. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.05.004 · Cited by 117
Tripathi, U., Nchioua, R., Prata, L. G. P. L., Zhu, Y., Gerdes, E. O. W., Giorgadze, N., Pirtskhalava, T., Parker, E., Xue, A., Espindola-Netto, J. M., et al. (2021) · Aging · doi:10.18632/aging.203560 · Cited by 88
Wesselingh, R., Butzkueven, H., Buzzard, K., Tarlinton, D., O'Brien, T. J., & Monif, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02066 · Cited by 83
Metadata
- Authors
- Anwar, M. A., Shah, M., Kim, J., & Choi, S.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2018-11-18
- Volume
- 39
- Issue
- 3
- Pages
- 1053-1090
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2900611152
- Cited by
- 275
- References
- 159
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.